US National Cancer Institute: Gene Fusions in Pediatric Sarcomas (R01)

The overall goal of this funding opportunity announcement (FOA) is to encourage the submission of research grant applications to investigate the molecular mechanisms by which oncogenic fusion genes and their gene products contribute to paediatric sarcoma initiation, progression, and metastasis. Better understanding of the molecular pathways activated by chromosomal translocations in pediatric sarcomas, and their relationship to oncogenesis and tumour progression, can elucidate mechanisms of cancer pathogenesis and potentially lead to novel therapeutics.

  • Funding Opportunity Announcement (FOA) Number: PA-16-251
  • This opportunity uses the R21 Exploratory/Developmental Research Grants funding mechanism.

Funding & Duration

Application budgets are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is 5 years.


Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.

Submission Requirements & Due Date

Further Information

Need Help?

This entry was posted in Engineering, Computer & Mathematical Sciences, Funding by Award Type, Grants (Project Funds), Health & Medical Sciences, International Funding, Sciences and tagged . Bookmark the permalink.

Comments are closed.